1 month Competition will make weight-loss drugs better, cheaper and biggerThe Economist Novo Nordisk and Eli Lilly face a growing number of challengers Eli Lilly (LLY) X
24 hours RFK Jr. Spooks Weight-Loss Stocks. Should Eli Lilly, Novo Nordisk Be Worried?Investor's Business Daily X
4 days Here’s Why Eli Lilly and Company (LLY) is on Detractors’ List of Madison Sustainable Equity FundInsider Monkey X
5 days Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should KnowZacks X
6 days Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready To Meet Demand?The Wall Street Journal X
1 week Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand?Investor's Business Daily X
2 weeks Eli Lilly and Company (LLY): Ken Fisher’s Bet on a Pharma Giant’s Growth PotentialInsider Monkey X
2 weeks Eli Lilly and Company (LLY): Among the Best Low Volatility Stocks to Invest In NowInsider Monkey X
2 weeks Eli Lilly Just Hit a Milestone That Disappointed. Here’s Why You Should Still Buy the Stock.The Motley Fool X
3 weeks Americans seeking Eli Lilly and Novo Nordisk’s weight-loss drugs turn to compounded marketFast Company X
3 weeks Eli Lilly Earnings Have Wall Street Asking New Questions About GLP-1 Drugs. Is Something Going Wrong?Yahoo Finance X
3 weeks Eli Lilly and Company (NYSE:LLY): Among The 10 Best S&P 500 Stocks to Buy According to Hedge FundsInsider Monkey X